Adamas Pharmaceuticals Inc (NASDAQ:ADMS) saw some unusual options trading on Tuesday. Stock investors purchased 1,604 call options on the stock. This is an increase of approximately 1,504% compared to the typical daily volume of 100 call options.
Several institutional investors and hedge funds have recently modified their holdings of ADMS. Alliancebernstein L.P. boosted its stake in shares of Adamas Pharmaceuticals by 2.6% in the second quarter. Alliancebernstein L.P. now owns 717,617 shares of the specialty pharmaceutical company’s stock worth $12,551,000 after buying an additional 17,972 shares during the last quarter. Granite Point Capital Management L.P. boosted its position in Adamas Pharmaceuticals by 11.9% during the second quarter. Granite Point Capital Management L.P. now owns 263,515 shares of the specialty pharmaceutical company’s stock worth $4,609,000 after purchasing an additional 28,000 shares in the last quarter. Vanguard Group Inc. boosted its position in Adamas Pharmaceuticals by 4.0% during the second quarter. Vanguard Group Inc. now owns 745,237 shares of the specialty pharmaceutical company’s stock worth $13,034,000 after purchasing an additional 28,818 shares in the last quarter. Citadel Advisors LLC purchased a new position in Adamas Pharmaceuticals during the second quarter worth approximately $606,000. Finally, Virtu KCG Holdings LLC purchased a new position in Adamas Pharmaceuticals during the second quarter worth approximately $184,000. Hedge funds and other institutional investors own 79.40% of the company’s stock.
Adamas Pharmaceuticals (NASDAQ:ADMS) opened at $37.39 on Friday. Adamas Pharmaceuticals has a 1 year low of $13.50 and a 1 year high of $38.75. The stock has a market capitalization of $834.62, a PE ratio of -11.09 and a beta of 1.13. The company has a debt-to-equity ratio of 0.41, a quick ratio of 8.32 and a current ratio of 8.35.
Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.01) by ($0.03). The firm’s quarterly revenue was down 99.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.66) earnings per share. equities analysts predict that Adamas Pharmaceuticals will post -3.84 earnings per share for the current fiscal year.
ADMS has been the subject of a number of recent research reports. Zacks Investment Research upgraded Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, September 21st. Noble Financial restated a “buy” rating and set a $33.00 price objective on shares of Adamas Pharmaceuticals in a report on Friday, September 29th. Piper Jaffray Companies restated an “overweight” rating and set a $30.00 price objective on shares of Adamas Pharmaceuticals in a report on Wednesday, October 4th. ValuEngine cut Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, October 13th. Finally, Evercore ISI started coverage on Adamas Pharmaceuticals in a report on Monday, October 30th. They issued an “outperform” rating for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the stock. Adamas Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $44.86.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.